Genotyping Assays Market Size, Share, and Forecast 2026 to 2034

Genotyping Assays Market Definition

The genotyping assays market covers the kits, instruments, software, and services used to detect inherited or acquired DNA variants in human, animal, and plant samples. It spans polymerase chain reaction, microarray, sequencing, capillary electrophoresis, and mass spectrometry methods that read single markers or whole panels of variants.

Counted products include genotyping reagents and kits, arrays, analyzers sold for genotyping work, analysis software, and contract genotyping services. Whole genome sequencing is counted only where it is used to call variants inside a genotyping workflow, while sequencers bought for general research are excluded. Forensic identity testing, infectious disease detection, and tumor profiling for acquired mutations sit outside the boundary.

A genotyping assay moves through four stages. Samples of blood, saliva, tissue, or leaf are extracted, the DNA is amplified or bound to probes, a reader turns the signal into allele calls, and software compares the calls with a reference. Different vendors often serve each step, and therefore a single laboratory may buy from four or five suppliers before analysis begins.

Scale shows how far array-based genotyping has moved. Our Future Health, a United Kingdom research program, released genotype data for 755,000 participants in May 2026, covering 686,416 variants measured on a custom Illumina beadchip. Eurofins runs the genotyping laboratory for the program.

Targeted Genotyping Assays vs Whole Genome Sequencing: Key Differences

Attribute	Targeted Genotyping Assays	Whole Genome Sequencing
Question answered	Which known variants a sample carries	Every variant, including new ones
Typical use	Pharmacogenomic panels, cohort studies, breeding, and screening	Rare disease diagnosis and discovery research
Cost per sample	Low, and stable at high volume	Higher, and falling each year
Data volume	Small files that are simple to store	Very large files that need compute and storage
Turnaround	Hours to a few days	Several days with analysis
Growth direction	Steady, with panels getting broader	Fast, as cost per genome drops

Source: Polaris Market Research Analysis

Targeted assays stay popular because the question is often narrow. A clinician choosing a statin dose requires a handful of gene results, and a breeder ranking bulls requires a fixed marker set. Many laboratories use both, with arrays or panels for volume and sequencing for the cases that require a wider look.

Porter's Five Forces Analysis

Force	Intensity	Rationale
Bargaining power of suppliers	Moderate	Enzymes, probes, and plastics come from several makers, while array fabrication and instrument design rest with a few firms.
Bargaining power of buyers	Moderate to High	Large laboratories, health systems, and national programs buy in volume and negotiate multiyear reagent contracts.
Threat of new entrants	Low	Regulatory clearance, proven content, and installed instrument bases make it costly for newcomers to win clinical accounts.
Threat of substitutes	Moderate	Falling sequencing costs let broad panels replace some targeted assays, although cost and speed still favor targeted tests at volume.
Competitive rivalry	High	Large life science groups compete on platform reach, consumable pricing, and content for the same laboratories.

Source: Polaris Market Research Analysis

Substitution deserves the closest attention, as sequencing prices keep dropping and software now handles the data that once held laboratories back. Instrument makers respond by selling both array and sequencing systems, and therefore a switch between methods often stays inside one supplier.

Market Dynamics

Driver Impact Analysis

Driver	Impact on Market Growth	Time Horizon
Expanding pharmacogenomic testing	High	Short to Medium Term
Population genomics programs	High	Medium Term

Source: Polaris Market Research Analysis

Driver: Expanding Pharmacogenomic Testing Is Moving Genotyping Into Routine Prescribing, Creating Market Demand

Prescribing decisions for statins, antidepressants, and blood thinners depend on how a patient metabolizes each drug, and a genotype panel gives that answer before the first dose. Health systems that test at the point of prescribing require panels that run on common platforms, and that lifts demand for arrays and polymerase chain reaction kits. The pharmacogenomics market study follows the same shift from the testing side.

For example, in October 2025, Thermo Fisher Scientific launched the Applied Biosystems SwiftArrayStudio Microarray Analyzer with two new arrays, Axiom PharmacoPro and Axiom PangenomePro, aimed at genome-wide association studies and pharmacogenomic work. The company said the platform returns results in as little as 30 hours and cuts hands-on time by up to 40%, a gain that matters to laboratories processing large sample batches.

Pharmacogenomics is projected to grow at a CAGR of 14.1% from 2026 to 2034, since payers increasingly accept tests that prevent adverse drug reactions. Hospital pharmacy teams are adding genotype results to the patient record, and that creates repeat demand for consumables.

Driver: Population Genomics Programs Are Genotyping Hundreds of Thousands of Participants, Creating Market Demand

National programs genotype volunteers at a scale that earlier cohort studies never reached, and each program buys arrays, reagents, and laboratory services in bulk. Arrays remain the lower-cost route for very large cohorts, since one chip reads several hundred thousand variants at a fraction of the price of a whole genome. Data releases then feed target discovery at pharmaceutical firms, keeping laboratories busy after the first genotyping round.

For example, in June 2026, the United States National Institutes of Health released a dataset from its All of Us Research Program that includes 553,000 genotyping arrays and more than 535,000 whole genome sequences, drawn from over 747,000 participants. The release also added proteomics data for nearly 10,000 participants, and therefore researchers can link inherited variants to measured proteins.

Clinical and research testing sites are projected to grow at a CAGR of 13.2% from 2026 to 2034, as program samples and clinical referrals pass through the same facilities. Contract laboratories gain most, since they can absorb cohort work without buying new instruments.

Restraint: Uneven Reimbursement and Regulatory Uncertainty Are Slowing Clinical Test Adoption, Restraining Market Growth

Payers cover genotyping tests only where evidence of clinical use is strong, and coverage rules differ by insurer and country. Laboratories that build their own tests also face rules that have changed several times, making it hard to plan investment in new assays. Smaller laboratories often wait for clearer reimbursement before they add panels.

For example, in March 2025, a federal court in Texas vacated the rule that would have let the US Food and Drug Administration (FDA) regulate laboratory developed tests as medical devices. The agency signaled in August 2025 that it would rescind the rule. Laboratories remain under the Clinical Laboratory Improvement Amendments, and therefore the immediate burden eased, yet the path to uniform reimbursement is still unsettled.

Academic and Research Institutes is projected to register the slowest growth among end users, due to grant budgets that rise more slowly than clinical spending. The restraint therefore weighs most on research buyers and on smaller clinical laboratories.

Opportunity: Falling Sequencing Costs Are Creating Openings for Low-Pass and Targeted Sequencing Assays

Sequencing-based genotyping reads variants that arrays were not designed to detect, including rare and population-specific changes, and low-pass sequencing combined with imputation reaches array-like cost. Laboratories that adopt it can keep one workflow for research and clinical samples. Suppliers of library preparation kits and variant-calling software stand to gain.

For example, in June 2025, Mission Bio unveiled a single-cell genotype and targeted gene expression solution on its Tapestri platform, and Devyser launched a genomic blood typing assay in the same month. Both products read targeted variants with sequencing chemistry, a sign that the line between genotyping and sequencing is thinning.

Sequencing is projected to grow at a CAGR of 18.2% from 2026 to 2034, well ahead of Polymerase Chain Reaction, as consumable cost per sample keeps falling. Software and Bioinformatics gains alongside, since each sequencing run produces data that requires calling and annotation.

Opportunity: National Genome Programs in Asia and the Gulf Are Creating Demand for Locally Supplied Genotyping Capacity

National programs in India, China, and the Gulf states are building reference datasets of their own populations, because variant frequencies seen in European cohorts do not carry over. Arrays and panels tuned to these populations require local content design, giving regional suppliers and service laboratories an opening. Capacity built for sequencing programs often extends to genotyping.

For example, in February 2026, the Emirati Genome Programme published a study using genomic data from more than 500,000 citizens, and the program has sequenced more than 850,000 people toward a goal of one million genomes. India reported in May 2026 that its GenomeIndia Project had sequenced 10,074 people from 83 population groups and found about 44 million variants missing from global databases.

India is projected to grow at a CAGR of 20.7% from 2026 to 2034, the highest of any country in the study, and Saudi Arabia is projected to grow at 15.1%. Their starting revenue is small, and therefore these programs add little to the global total yet lift regional growth rates.

Trend: Suppliers Are Bundling Genotyping With Sequencing, Proteomics, and Analysis Software Into Single-Vendor Workflows

Suppliers want laboratories to buy genotyping, sequencing, and analysis from one source, and therefore portfolios are being redrawn through purchases and disposals. Buyers prefer fewer contracts and shared data formats, and smaller suppliers respond by narrowing to specialties where they can still win on content or price.

For example, in January 2026, Illumina completed its purchase of SomaLogic from Standard BioTools. The seller later agreed to sell its microfluidics business to Biomark Scientific for about USD 5.0 million, a deal completed on November 3, 2026. QIAGEN, meanwhile, finished its acquisition of Parse Biosciences in December 2025 and began an artificial intelligence collaboration with NVIDIA in May 2026.

Software and Bioinformatics is projected to grow at a CAGR of 17.5% from 2026 to 2034, since bundled workflows add analysis and interpretation to every kit sold. Mergers among large groups make life harder for small suppliers when the next round of laboratory contracts is awarded.

Value Chain Analysis

Stage	Activities	Representative Participants
Raw materials and oligonucleotides	Enzymes, primers, probes, plastics, and array substrates	Integrated DNA Technologies, Merck KGaA, and New England Biolabs
Assay design and manufacturing	Panels, arrays, and cartridge kits built for defined variant sets	Thermo Fisher Scientific, Illumina, and Agilent Technologies
Instruments and readers	Thermal cyclers, scanners, analyzers, and sequencers	Thermo Fisher Scientific, Roche, Bio-Rad Laboratories, and QIAGEN
Testing services	Contract genotyping for cohorts, clinics, and breeders	Eurofins Scientific, Laboratory Corporation of America Holdings, and NeoGenomics
Software and interpretation	Variant calling, annotation, reporting, and records integration	Illumina, QIAGEN Digital Insights, and laboratory software vendors

Source: Polaris Market Research Analysis

Value sits in the assay design and consumable layers, since each placed instrument pulls through kits for years. Instrument makers earn from installations and service contracts, while enzyme and plastics suppliers depend on volume and face price pressure from large buyers.

Margins differ by stage, with software and interpretation carrying recurring revenue and testing services depending on throughput. Laboratories that own their instruments buy reagents directly, and those that outsource pay a service fee that bundles consumables, labor, and analysis.

Genotyping Assays Market Segmentation Analysis

The five dimensions below are read one at a time, since buyers pick a product type, a method, an application, and a variant class for separate reasons.

Product Insights

Reagents and Kits accounted for 46.9% of product revenue in 2026, owing to the fresh enzymes, probes, plates, and cartridges that every sample consumes. A placed instrument pulls through consumables for years, and laboratories reorder on a fixed schedule. Kits built for pharmacogenomic and cardiovascular panels now sell into hospitals as well as research centers.

Instruments is expected to record steady growth, as laboratories replace older cyclers and scanners with systems that automate array and panel workflows. For example, in July 2026, Illumina raised its full-year revenue guidance after growth in the second quarter.

Software and Bioinformatics is anticipated to register the fastest growth among product groups, at a CAGR of 17.5% from 2026 to 2034, due to variant calling, interpretation, and reporting tools that laboratories now license for each platform. Cloud pipelines let small laboratories run analyses that once needed in-house servers. Genotyping Services is also expected to expand, as pharmaceutical firms and cohort programs outsource large batches to contract laboratories.

Demand for service work shows a pattern of its own. Pharmaceutical sponsors outsource large screening batches during trial startup, and breeders send samples in seasonal waves, and therefore contract laboratories plan staffing and reagent stocks months ahead. Those with strong sample tracking and fast turnaround keep customers over many seasons.

Pricing differs sharply across these four groups. Consumables are bought repeatedly at negotiated unit prices, instruments are bought once and serviced for years, software is licensed by the seat or by the run, and services are billed per sample. Suppliers that combine all four in one contract earn steadier revenue and make switching harder for the buyer.

Technology Insights

Polymerase Chain Reaction accounted for 35.7% of technology revenue in 2026, owing to quick turnaround, a low price per result, and a place in nearly every hospital laboratory. Real-time and digital formats read single variants within hours, and ready-to-run kits suit laboratories without bioinformatics staff. The digital PCR market study covers the high-precision end of this method.

Microarrays is expected to grow at a moderate pace, as large cohort studies keep choosing arrays for their cost per sample. One chip can read several hundred thousand variants, and imputation extends the result to millions more. For example, in October 2026, Thermo Fisher Scientific showed its SwiftArrayStudio analyzer, QuantStudio 7 Pro real-time PCR system, and QuantStudio Absolute Q digital PCR system at the annual human genetics conference in Montreal.

Sequencing is anticipated to register the fastest growth among technologies, at a CAGR of 18.2% from 2026 to 2034, attributed to low-pass whole genome and targeted panel methods that now rival arrays on price for some projects. Laboratories also value the ability to find rare and new variants in the same run. The next generation sequencing market report sizes the wider sequencing business.

Capillary Electrophoresis retains a niche role, driven by fragment analysis in microsatellite typing and by its use as a confirmation step in clinical laboratories. Mass Spectrometry remains a specialist option, since matrix-assisted laser desorption panels suit multiplexed variant screening at a low cost per marker.

Reagent supply chains also deserve attention, since enzymes, probes, and plastic plates come from a small group of makers and a shortage in one input can slow many laboratories. Buyers increasingly ask for second sources and for stock held close to their sites, and suppliers with regional warehouses benefit.

Application Insights

Diagnostics and Personalized Medicine accounted for 31.6% of application revenue in 2026, driven by inherited disease screening, carrier testing, and companion diagnostic work that guides therapy choice. Clinical laboratories favor proven kits that fit existing instruments, and established reimbursement keeps volumes predictable. The molecular diagnostics market study covers the wider testing business.

Pharmacogenomics is anticipated to register the fastest growth among applications, at a CAGR of 14.1% from 2026 to 2034, due to the growing number of drug labels and guidelines that refer to a gene result. For example, in August 2026, QIAGEN reported that sales of consumables tied to pharmaceutical co development agreements rose at a double-digit rate in the second quarter, led by companion diagnostics for targeted therapies.

Agricultural Biotechnology is expected to expand steadily, as breeders use marker panels to select crops for yield and stress tolerance. Animal Genetics is a smaller but established application, attributed to genomic selection in dairy and beef herds, where one test can rank an animal before it breeds.

Drug Discovery and Development is a growing application, owing to the genotyping of trial participants to select likely responders and to study safety. Sponsors run these tests early, and therefore the revenue arrives well before any product reaches the market.

End User Insights

Diagnostic and Research Laboratories contributed 32.2% of end-user revenue in 2026, driven by everyday patient testing and outsourced studies for drug developers. Reference laboratories buy in large volumes and push suppliers for lower prices per sample. Spending moves with test volumes, and therefore seasonal and reimbursement shifts show up quickly.

Pharmaceutical and Biopharmaceutical Companies is expected to record strong growth, as trial sponsors genotype participants to stratify patients and to study safety. Companion diagnostic agreements also bring these buyers into long-term supply contracts with kit makers.

Agricultural and Animal Breeding Organizations form a smaller but steady buyer group, owing to herd and seed programs that genotype thousands of animals or lines each year. For example, in December 2025, the Global Institute for Food Security at the University of Saskatchewan and the Canadian Beef Improvement Network launched a Canadian-based DNA testing platform, and therefore producers no longer have to ship samples abroad.

Academic and Research Institutes remain a steady buyer group, due to cohort studies, core facilities, and training programs that buy arrays and reagents under grants. Grant cycles make orders lumpy, although long-running consortia provide a steady base.

Variant Type Insights

Single Nucleotide Polymorphisms accounted for 60.6% of variant type revenue in 2026, because most pharmacogenomic markers, array content, and breeding panels target single base changes. Low-cost, well-characterized assays exist for these variants. For example, in May 2025, Almac Diagnostic Services launched a PNPLA3 genotyping kit for liver disease research, a single variant assay of the kind laboratories add to existing panels.

Copy Number Variations is anticipated to register the fastest growth among variant types, at a CAGR of 15.7% from 2026 to 2034, as rare disease and cancer laboratories look beyond single base changes. Arrays and sequencing can both measure gains and losses of DNA segments, and software has made the calls easier to read.

Insertions and Deletions is a smaller but expanding variant class, due to sequencing-based panels that detect small insertions and deletions that older array designs miss. Short Tandem Repeats retain a steady role, attributed to capillary electrophoresis-based typing in breeding, parentage, and cell line authentication.

Other Variants covers structural rearrangements, methylation marks, and haplotype calls, and these are small in revenue but are the focus of new product work. Laboratories that already run arrays or sequencers can add such calls through software updates, because analysis tools reuse existing raw data, so the barrier to entry is lower than for new hardware.

Genotyping Assays Market Regional Analysis

Regional demand follows research funding, clinical testing capacity, and breeding industries. North America holds the largest share of revenue, Europe and Asia Pacific follow with similar shares as national programs narrow the gap, while Latin America and Middle East & Africa start from smaller bases.

North America Genotyping Assays Market Trends

Revenue in North America reached 40.0% of the genotyping assays market total in 2026, driven by drug developers, large reference laboratories, and federal research programs in the United States. Mexico is expected to register the fastest growth in the region, as contract laboratories and breeding programs expand there. For example, in August 2025, the US Food and Drug Administration signaled its intent to rescind its laboratory developed test rule, leaving test oversight with the existing Clinical Laboratory Improvement Amendments framework.

Canada is expected to expand steadily, as provincial programs and the new domestic beef testing platform build local capacity. Supplier headquarters sit mostly in the United States, and therefore regional demand and company results move closely together.

Large reference laboratories dominate clinical volumes and negotiate hard on price, while academic centers buy arrays and reagents through grants and consortium contracts. Several states also fund agricultural genomics, and therefore breeding programs add a second source of steady demand.

Europe Genotyping Assays Market Trends

Europe held one of the largest regional shares in 2026, owing to academic cohort programs, strong breeding industries, and established reimbursement for clinical genetic tests in Germany, France, and the United Kingdom. Germany is the biggest country market, while the Netherlands registers the fastest growth of the six. For example, in May 2026, Our Future Health released imputed genotypes covering 159.6 million variants, built against a UK Biobank whole genome reference panel and offered with inferred genetic ancestry.

Europe is projected to grow steadily over the forecast period. Data protection rules and public funding for biobanks shape purchases, and laboratories often prefer kits that carry European conformity marking. Agrigenomics adds steady demand in the Netherlands, France, and Germany.

Procurement in Europe often runs through public tenders, and therefore price and local service coverage weigh heavily. Several national health systems are also building pharmacogenomic programs, and their buying rules favor suppliers with European conformity marking and local technical support teams.

Asia Pacific Genotyping Assays Market Trends

Asia Pacific is the fastest-growing region, with a CAGR of 14.6% from 2026 to 2034, driven by national genome programs in China, India, South Korea, and Australia and by expanding clinical laboratory networks. China holds the biggest national market in the region, and India registers the fastest growth. For example, in November 2026, Illumina announced that it had been selected to help bring precision medicine into everyday healthcare in Singapore.

Manufacturing capacity in the region is growing as well. BGI Group and its sequencing unit MGI Tech supply platforms from within Asia, and therefore domestic buyers have a local alternative to imported systems. Japan keeps a mature base in pharmacogenomics and arrays, while Australia leads in animal and crop genetics.

Contract laboratories in South Korea, Taiwan, and Singapore serve both domestic hospitals and overseas drug developers, and their volumes rise with every new trial. India adds a large base of academic laboratories and growing diagnostic chains, which makes it the most closely watched country in the region.

Latin America Genotyping Assays Market Trends

Latin America is projected to register healthy growth over the forecast period. Growth is attributed to Brazil and Mexico adding testing capacity for rare disease, oncology, and breeding work. Brazil has the biggest national market and also grows faster than Argentina. For example, in February 2026, the Brazilian laboratory NeoGenomica and MGI Tech described a partnership to widen rare disease diagnosis, while the Genomas Raros program aims to scale toward 100,000 genomes nationally.

Public hospitals and private laboratory chains buy different products. Hospital programs favor low-cost panels and screening kits tied to national lists of reimbursed tests, while private chains buy sequencers and arrays for wider menus. Currency swings and import duties raise prices, and therefore local distributors with service teams hold a strong position.

Middle East & Africa Genotyping Assays Market Trends

Middle East & Africa is projected to register strong growth over the forecast period. Growth is driven by national genome programs in the Gulf, led by Saudi Arabia and the Emirates. Saudi Arabia is both the biggest and the fastest-growing country there. For example, in April 2025, the Emirati Genome Programme reported 815,000 samples, up from 600,000 in June 2024, and the Emirates Genome Council found more than five million novel variants in a study of 50,000 samples.

High rates of inherited disease linked to consanguinity give these programs a clear clinical purpose, and governments fund them as part of wider health reform. Africa south of the Sahara is much smaller in revenue, although South Africa hosts research centers and several breeding programs, and international consortia are building genotyping capacity there.

Genotyping Assays Market Competitive Landscape

The field splits into three layers, as large life science groups sell instruments, consumables, and software as one platform, specialist firms sell panels and single-cell or targeted solutions, and service laboratories sell testing capacity. A supplier usually wins a laboratory once and then supplies it for the life of the instrument.

Illumina supplies the custom array used by Our Future Health, while Thermo Fisher Scientific has answered with a new analyzer and two arrays aimed at the same population studies. Company results show demand holding up unevenly, since Thermo Fisher Scientific revenue rose 9% in its third quarter and Illumina revenue rose 9.5% in its second, but QIAGEN net sales were flat in the second quarter.

Portfolio moves continue to shift positions. Standard BioTools exited proteomics and then microfluidics within ten months, and its former assets now sit inside larger groups. Market share moves slowly, and companies that hold proven content, installed instrument bases, and clinical approvals are best placed to gain it, as laboratories rarely change platforms once a workflow-passes audit.

Vendor Landscape Snapshot

Company	Vendor Positioning	Role
Thermo Fisher Scientific Inc.	Leader	Axiom arrays, real-time PCR, and the SwiftArrayStudio analyzer
Illumina, Inc.	Leader	Infinium arrays and sequencing, including a custom array for Our Future Health
Danaher Corporation	Challenger	Oligonucleotides and diagnostics through Integrated DNA Technologies and Cepheid
QIAGEN N.V.	Challenger	PCR systems, QIAstat Dx, and companion diagnostic partnerships
F. Hoffmann-La Roche Ltd	Challenger	Molecular diagnostics instruments and PCR-based tests
Agilent Technologies, Inc.	Challenger	Microarray scanners and sample preparation
Bio-Rad Laboratories, Inc.	Challenger	Droplet digital PCR and real-time PCR systems
Eurofins Scientific SE	Challenger	Contract genotyping laboratories, including work for Our Future Health
Revvity, Inc.	Challenger	Reagents and screening products for genetic testing
BGI Group	Challenger	Sequencing platforms and genomic services through MGI Tech and BGI Genomics
Merck KGaA	Niche Player	Oligonucleotides and reagents through its life science business
Standard BioTools Inc.	Niche Player	Microfluidic genotyping tools until the 2026 sale of that business
Mission Bio	Emerging Player	Single-cell genotyping on the Tapestri platform

Source: Polaris Market Research Analysis

Genotyping Assays Market Technology and Innovation Landscape

Innovation centers on shorter turnaround, wider content, and lower cost per sample. Newer analyzers combine scanning, hybridization, and staining steps in one device, while low-pass sequencing with imputation extends array-like results to larger variant sets.

Population specific content is the second theme. Arrays and panels designed around European cohorts miss variants that are common elsewhere, and therefore suppliers now build content for particular regions and drug-gene pairs. The PharmacoPro and PangenomePro arrays that Thermo Fisher Scientific introduced in October 2025 follow that approach.

Single-cell genotyping adds a further layer, as products such as the Tapestri platform read variants in thousands of individual cells at once, helping researchers study how cell populations change over time. Data tools are moving in parallel, with artificial intelligence now used to rank variants and to reanalyze older cases when new evidence appears.

Technology and Innovation Landscape Snapshot

Area	Role	Status and Representative Developers
Pharmacogenomic arrays	Read drug response variants across diverse populations	Production, with Thermo Fisher Scientific and Illumina
Integrated array analyzers	Combine four genotyping steps in one instrument	Launched in 2025 by Thermo Fisher Scientific
Digital and real-time PCR	Read single variants quickly and at low cost	Production, with QIAGEN, Bio-Rad Laboratories, and Thermo Fisher Scientific
Low pass sequencing with imputation	Match array content at lower cost for large cohorts	Scaling, with Illumina and MGI Tech
Single-cell genotyping	Read variants in individual cells	Early commercial use, with Mission Bio
Cloud variant analysis	Call, annotate, and report variants without local servers	Expanding, with QIAGEN Digital Insights and Illumina

Source: Polaris Market Research Analysis

Use Case Analysis

Pharmacogenomic Panels in Hospitals and Pharmacies

Health systems order panels that cover genes involved in the metabolism of common drugs, and results are stored so that later prescriptions can draw on them. Pharmacists often manage the workflow, and therefore suppliers that integrate with hospital records win repeat orders. One test can inform many prescriptions over a patient's lifetime.

Adoption is slowed by the need to train prescribers and by uneven payment for tests that are ordered before any illness appears. Hospitals that publish their own outcome data find it easier to win budget, and suppliers increasingly help by offering reporting software and clinical support staff.

Population Cohorts and Biobanks

Biobanks genotype hundreds of thousands of volunteers on arrays and then share the data with researchers. Orders are large and planned years ahead, and therefore suppliers compete on price per sample and on custom content. The same data later supports drug target discovery at pharmaceutical firms.

Quality control matters as much as price here, since an error in one plate can touch thousands of participants. Biobanks therefore ask suppliers for plate-level reports, consistent chemistry across years, and support for sample tracking, and these requirements favor large vendors with proven scale.

Animal and Plant Breeding

Breeders genotype animals and seed lines with marker panels, and therefore selection can happen before traits show. Dairy and beef programs run thousands of samples a year, and national testing platforms are appearing to keep data and sample flows inside a country. Low cost per sample and sample tracking decide most contracts.

Seasonal demand shapes ordering, as sample collection peaks around breeding and planting cycles. Producers also want results that plug into herd or crop management software, and therefore suppliers that provide data in standard formats gain an edge over those that deliver only raw files.

Rare Disease and Cancer Research Laboratories

Laboratories of this kind use genotyping to follow known variants and to confirm findings from sequencing. Copy number and structural variant calls matter more here, as does the ability to analyze single cells. Turnaround and clear reporting count as much as price.

Many of these laboratories sit inside universities and children's hospitals, where grants and philanthropic funds set the budget. Orders arrive in bursts after funding rounds, and suppliers that offer flexible reagent rental or shared instrument access keep these accounts through the gaps.

Clinical Trial Stratification

Sponsors genotype participants at screening to select patients who are likely to respond or to avoid those at risk of side effects. Contract laboratories run the work to a defined protocol, and therefore suppliers that offer proven kits and audit trails earn trust. Companion diagnostics grow out of the same work.

Timelines are fixed by trial schedules, and therefore late delivery of kits or results is costly for the sponsor. Contract laboratories therefore keep safety stock of reagents and prefer suppliers with reliable shipping, documented lot histories, and regulatory support for later submissions.

Premium Insights and Forward Outlook

Single-Gene Orders Will Give Way to Multi-Gene Panels

Laboratories that test one drug-gene pair today will add more genes once results sit in the patient record, since the marginal cost of an extra marker is small. Suppliers of arrays and flexible panels benefit, and reimbursement for broader panels will decide how fast the change happens.

Early signs are visible in pharmacy programs that test for several drug-gene pairs at once and store the results for later use. Payers will want evidence that broader panels lower the cost of adverse reactions, and suppliers that fund such studies stand to gain preferred status.

Population-Specific Content Will Decide Array Wins

Buyers outside Europe and North America now ask whether content matches the people they test. Suppliers that design arrays with regional programs, or license data from them, will hold an edge over those selling one global design. National programs in Asia and the Gulf are likely to shape these specifications.

Licensing arrangements with national programs may become a source of competitive advantage, since access to local reference data speeds array design. Smaller suppliers can partner with universities and public institutes to build content that large vendors do not offer.

Sequencing Will Absorb Arrays Mainly at the High End

Falling sequencing cost will move rare disease and discovery work away from arrays, yet large cohorts and routine panels will keep using arrays and polymerase chain reaction because cost per sample and speed still favor them. Instrument makers selling both methods are well placed in either case.

The pace of this shift depends on laboratory budgets and on how quickly interpretation software matures. Where results feed directly into patient care, many laboratories will keep the cheaper and faster method for routine work and reserve sequencing for hard cases.

Bundled Workflows Will Concentrate Spend

Large suppliers are assembling genotyping, sequencing, proteomics, and software into single contracts, and that raises the value of installed bases. Small firms without distinct content or clinical approvals will face pressure to partner or to sell.

Recent portfolio moves show how quickly positions can change, since a business that was bought for growth can be sold within months. Buyers of bundled contracts should therefore ask suppliers how long product lines will be supported before they commit.

Key Players in the Genotyping Assays Market

• Thermo Fisher Scientific Inc.
• Illumina, Inc.
• Danaher Corporation
• QIAGEN N.V.
• F. Hoffmann-La Roche Ltd
• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• Eurofins Scientific SE
• Revvity, Inc.
• BGI Group
• Merck KGaA
• Standard BioTools Inc.
• Mission Bio

Industry Developments

• June 2026: The National Institutes of Health opened All of Us data release CDRv9, adding long-read genomes from more than 14,500 participants and RNA sequencing from nearly 9,000 (Source: National Institutes of Health).
• May 2026: Our Future Health opened its fourteenth data release, linking 755,000 participants to array genotypes and inferred kinship (Source: Our Future Health).
• January 2026: Illumina closed its acquisition of SomaLogic, bringing the SomaScan proteomics business inside the company (Source: Illumina).
• October 2025: Thermo Fisher Scientific introduced an analyzer that combines four genotyping processes in one device and said the platform can expand to methylation, epigenetics, reproductive health, and agrigenomics (Source: Thermo Fisher Scientific).

Genotyping Assays Market Report Segmentation

By Product Outlook (Revenue, USD Billion, 2021 to 2034)

• Reagents and Kits
• Instruments
• Software and Bioinformatics
• Genotyping Services

By Technology Outlook (Revenue, USD Billion, 2021 to 2034)

• Polymerase Chain Reaction
• Microarrays
• Sequencing
• Capillary Electrophoresis
• Mass Spectrometry
• Others

By Application Outlook (Revenue, USD Billion, 2021 to 2034)

• Pharmacogenomics
• Diagnostics and Personalized Medicine
• Agricultural Biotechnology
• Animal Genetics
• Drug Discovery and Development
• Others

By End User Outlook (Revenue, USD Billion, 2021 to 2034)

• Pharmaceutical and Biopharmaceutical Companies
• Diagnostic and Research Laboratories
• Academic and Research Institutes
• Agricultural and Animal Breeding Organizations
• Other End Users

By Variant Type Outlook (Revenue, USD Billion, 2021 to 2034)

• Single Nucleotide Polymorphisms
• Insertions and Deletions
• Copy Number Variations
• Short Tandem Repeats
• Other Variants

By Regional Outlook (Revenue, USD Billion, 2021 to 2034)

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Taiwan
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • South Africa
  • Rest of Middle East & Africa

Genotyping Assays Market Report Scope

Report Attribute	Details
Market Size in 2025	USD 20.40 Billion
Market Size in 2026	USD 23.32 Billion
Revenue Forecast by 2034	USD 58.55 Billion
CAGR	12.2% (2026 to 2034)
Base Year	2025
Historical Data	2021 to 2024
Forecast Period	2026 to 2034
Quantitative Units	Revenue in USD Million and USD Billion, and CAGR in percent
Report Coverage	Revenue Forecast, Growth Factors, Competitive Landscape, Industry Trends, and Strategic Analysis of the genotyping assays market
Segments Covered	By Product, Technology, Application, End User, Variant Type, and Region
Regional Scope	North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Competitive Landscape	Company Profiling, Product Benchmarking, Financial Analysis, Market Developments, and Strategic Initiatives
Report Format	PDF and Excel
Customization	Available by Country, Region, and Segment
Research Team	Polaris Market Research & Consulting, Inc. research team
Last Updated	November 5, 2026

Source: Polaris Market Research Analysis

Why Choose Polaris Market Research

Each number in this study comes from a single country by segment model, letting a reader trace any regional figure down through its countries and segments.

Besides the standard categories, the report splits revenue by variant type, showing spending move from single base changes toward copy number variation, and it tracks the shift from arrays to sequencing inside each application.

Four principal sources are credited by name, with a date wherever the source gives one. Planning teams can then see whether a claim comes from company releases or public research programs.

Polaris can tailor the study to a single country, segment, or set of companies. To buy this report or request customization, contact Polaris Market Research & Consulting, Inc.

Research Methodology

Research Approach

Sizing starts from the supplier side. It covers the assays, kits, reagents, instruments, software, and contract services that read known genetic variants in human, animal, and plant samples. Standalone discovery sequencing services, newborn screening programs, and general laboratory equipment are left out. The model spans 2021 to 2034 with 2025 as the base year, reports USD Million and USD Billion, and holds five segment dimensions across 25 countries and country groups in five regions. See the research methodology page for the wider Polaris framework.

Secondary Research

The secondary evidence base draws on four principal sources: the National Institutes of Health and Our Future Health among public research programs, and Thermo Fisher Scientific and Illumina among company releases. Most were published during the past year, and the remainder carry their own dates in the text. Each source is credited by name, and other public disclosures were used only to cross-check scope and context.

Primary Research

The research combines primary interviews with secondary research, and Polaris follows its standard interview process. The interviews cover manufacturers, distributors and channel partners, and industry experts and consultants. They are used to validate secondary estimates, segment shares, regional trends, and growth drivers.

Data Structuring

All inputs were expressed in USD for each year, and segment boundaries were frozen ahead of sizing. A product serving several technologies is placed under its main use to prevent double counting, and standalone discovery sequencing was removed to keep totals inside the scope.

Market Size Estimation

Bottom-up work begins in each national market, where supplier revenue, laboratory test volumes, and consumable content per platform feed every segment figure. Country figures then add into regions, and regional figures into the global total.

The top-down view places the 2025 base at USD 20.40 Billion and compares it with company disclosures and third-party size estimates. Those sizes diverge since each analyst firm sets its own scope, and the Polaris base sits more than six percent from each comparable figure.

Forecasting

Projections follow clinical test volumes, cohort enrollment, and breeding program output. Growth eases from one year to the next along a single path that yields the stated CAGR, while segment and regional mixes shift slowly between 2025 and 2034 as sequencing and digital methods take share.

Data Triangulation and Validation

The model passed four consistency tests. Shares add to 100% in each year. Country figures sum to regional totals and then to the global figure, and history and forecast follow one easing growth rate. The 2025 base was also set against the range of comparable third-party estimates.

Limitations

Genotyping, sequencing, and general molecular diagnostics overlap at the edges, which is why third-party sizes differ from the figures here. Suppliers that are privately held report little revenue, and their regional shares are therefore estimates. Market figures in this report are Polaris estimates.

Research Methodology Phases

Phase	Focus	Evidence / Output
Scope and Setup	Market boundary, segments, and regions	Fixed scope and segment list
Secondary Data Collection	Public research program notices and company releases	Four credited sources with dates
Primary Research	Talks with manufacturers, distributors, and domain experts	Checked shares, trends, and drivers
Data Structuring	Annual USD figures with fixed boundaries	Inputs with no double counting
Bottom-Up Estimate	Country and segment estimates	Regional and global totals
Top-Down Estimate	Global base for 2025 and its segment mix	Base compared with public estimates
Forecasting	Annual growth path to 2034	Stated CAGR
Triangulation and Validation	Share, total, and range checks	Four passed checks
Output	Report tables and text	A single data set behind every table

Source: Polaris Market Research Analysis

Data Sources by Type

Type of Source	Named Examples	Role in the Estimates
Government and public research programs	National Institutes of Health, Our Future Health	Cohort data releases and genotyping scale
Company releases	Illumina, Thermo Fisher Scientific	Launches and portfolio moves

Source: Polaris Market Research Analysis